CJC-1295 (no DAC) vs Ipamorelin
Compare the research, key figures and safety notes.
How they differ
The classic growth-hormone combo. One (CJC-1295 without DAC) nudges the gland the way the body's own release signal does; the other (ipamorelin) pushes it a different way, so together they add up. Both clear fast — the CJC form within about half an hour, ipamorelin within a couple of hours — so they act as short bursts, not a steady level. Ipamorelin has one human blood-level study; this CJC form has no human trial of its own, so its numbers come from the community.
Side by side
| Measure | CJC-1295 (no DAC) | Ipamorelin |
|---|---|---|
| Category | Growth hormone axis | Growth hormone axis |
| Evidence | D · From community reports | A · Human dose research |
| Route | Route not established | Intravenous |
| Half-life | 0.5 h | 2 h |
| Typical vial | 2 / 5 mg | 5 / 10 mg |
| Research amount | 100–300 mcg | 100–300 mcg |
| Common schedule | Every day | Every day |
| Cycle / break | — | 8–12 / 4 |
| Studied for | Growth-hormone release | Growth-hormone release |
These amounts and schedules are figures discussed in research and community reports, shared for learning — not a recommendation and not medical advice. A step-by-step dosing schedule exists only where a human trial backs it; the evidence tier tells you which.
Decay curves, overlaid
Each line is scaled to that compound's own first dose, so the chart shows how each one builds up over time — not how the compounds' doses compare to one another, which these different molecules share no common unit for.
How they combine
Educational reference on commonly-discussed combinations, not medical advice. Combining compounds can change how each behaves — read this as a prompt to research, not a clearance.